Preclinical evaluation of.sup.188Re-HYNIC-PSMA as a novel therapeutic agent

Preclinical evaluation of.sup.188Re-HYNIC-PSMA as a novel therapeutic agent

In this study, optimized preparation, quality control, cell assessments and biostribution of .sup.188Re-HYNIC-PSMA in normal rats and tumor bearing mice are studied. Optimized conditions for radiolabeling were evaluated and radiochemical purity (> 99%) was investigated using ITLC and HPLC methods...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of radioanalytical and nuclear chemistry 2022-02, Vol.331 (2), p.841
Hauptverfasser: Hadisi, Maliheh, Vosoughi, Naser, Yousefnia, Hassan, Bahrami-Samani, Ali, Zolghadri, Samaneh, Vosoughi, Sara, Alirezapour, Behrouz
Format: Artikel
Sprache:eng
Schlagworte:
Health aspects
High performance liquid chromatography
Measurement
Quality control
Radiation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this study, optimized preparation, quality control, cell assessments and biostribution of .sup.188Re-HYNIC-PSMA in normal rats and tumor bearing mice are studied. Optimized conditions for radiolabeling were evaluated and radiochemical purity (> 99%) was investigated using ITLC and HPLC methods. .sup.188Re-HYNIC-PSMA was stable both in PBS (4 °C) and in human serum (37 °C) even after 48 h. The results showed the complex was cleared from the blood very fast via urinary track. This new radiolabeled compound has a high potential to be considered as an agent for the treatment of patients with PSMA expressing tumors however more biological studies are still needed.
ISSN:0236-5731
DOI:10.1007/s10967-021-08173-1